|
Contents |
down TOP
|
|
|
|
|
|
|
Case
Reports
|
 
|
|
|
|
Amene CS, Yeh-Nayre LA, Crawford JR.
Secondary glioblastoma multiforme in a child with
disseminated juvenile pilocytic astrocytoma.
Case
Rep Oncol Med. 2012;2012:290905. doi: 10.1155/2012/290905. Epub 2012
Nov 19.
Abstract
| Full
text |
Related citations
|
|
|
Hiniker A, Hagenkord JM, Powers MP, Aghi MK, Prados MD, Perry A.
Gliosarcoma
arising from an oligodendroglioma (oligosarcoma).
Clin Neuropathol.
2012 Dec 20. [Epub ahead of print]
Abstract
| Related
citations
|
|
|
Lettau M, Jedrusik P, Laible M.
Dural
Metastases of a Glioblastoma.
Clin Neuroradiol.
2012 Dec 23. [Epub ahead of print]
Abstract | Related
citations
|
|
|
|
|
|
Classification
|
|
|
|
|
|
|
|
Complications
|
|
|
|
|
Lomax AJ, Hill PA, Ashley DM.
Case report of interstitial nephritis induced
by bevacizumab therapy for glioblastoma multiforme.
J Oncol Pharm Pract. 2012 Dec
12. [Epub ahead of print]
Abstract
|
Related citations
|
|
|
|
|
|
Detection
|
|
|
|
|
|
|
|
Diagnosis
& Evaluation
|
|
|
|
|
Farace P, Amelio D, Ricciardi GK, Zoccatelli G, Magon S, Pizzini F,
Alessandrini F, Sbarbati A, Amichetti M, Beltramello A.
Early
MRI changes in glioblastoma in the period between surgery and adjuvant
therapy.
J Neurooncol.
2013 Jan;111(2):177-85. doi: 10.1007/s11060-012-0997-y. Epub 2012 Dec 22.
Abstract
| Full
text | Related
citations
|
|
|
Liang D, Schulder M.
The role of intraoperative magnetic resonance imaging
in glioma surgery.
Surg
Neurol Int. 2012;3(Suppl 4):S320-7. doi: 10.4103/2152-7806.103029.
Epub 2012 Oct 31.
Abstract
| Full
text |
Related citations
|
|
|
|
|
|
Epidemiology
& Risk Factors
|
|
|
|
|
|
|
|
Etiology
& Pathogenesis
|
|
|
|
|
Wagoner MP, Roopra A.
A REST derived gene signature stratifies glioblastomas
into chemotherapy resistant and responsive disease.
BMC Genomics. 2012 Dec
7;13:686. doi: 10.1186/1471-2164-13-686.
Abstract |
Full text |
Related citations
|
|
|
|
|
|
Integrative
Medicine
|
|
|
|
|
|
|
|
Overall
Management
|
|
|
|
|
|
|
|
Meetings
|
|
|
|
|
|
|
|
Prevention
|
|
|
|
|
|
|
|
Prognosis
& Outcome
|
|
|
|
|
Choi Y, Song YJ, Lee HS, Hur WJ, Sung KH, Kim
KU, Choi SS, Kim SJ, Kim DC.
Epidermal growth factor receptor is related to poor
survival in glioblastomas: single-institution experience.
Yonsei Med J.
2013 Jan 1;54(1):101-7. doi: /10.3349/ymj.2013.54.1.101.
Abstract
| Full text
|
Related citations
|
|
|
Leibetseder A, Ackerl M, Flechl B, Wöhrer A,
Widhalm G, Dieckmann K, Kreinecker SS, Pichler J, Hainfellner J, Preusser M,
Marosi C.
Outcome and molecular characteristics of adolescent
and young adult patients with newly diagnosed primary glioblastoma: a study
of the Society of Austrian Neurooncology (SANO).
Neuro Oncol. 2013
Jan;15(1):112-21. doi: 10.1093/neuonc/nos283. Epub 2012 Dec 7.
Abstract |
Related citations
|
|
|
Melguizo C, Prados J, González B, Ortiz R, Concha A, Alvarez PJ, Madeddu R,
Perazzoli G, Oliver JA, López R, Rodríguez-Serrano F, Aránega A.
MGMT
promoter methylation status and MGMT and CD133 immunohistochemical
expression as prognostic markers in glioblastoma patients treated with
temozolomide plus radiotherapy.
J Transl Med.
2012 Dec 17;10:250. doi: 10.1186/1479-5876-10-250.
Abstract
| Full
text | Related
citations
|
|
|
|
|
|
Psychosocial
Aspects
|
|
|
|
|
|
|
|
Stem
Cells
|
|
|
|
|
|
|
|
Treatment
|
|
|
|
Overviews
|
|
|
|
|
|
|
|
Laboratory
Investigations
|
|
|
|
|
Arcella A, Biagioni F, Antonietta Oliva M, Bucci D, Frati A, Esposito V,
Cantore G, Giangaspero F, Fornai F.
Rapamycin
inhibits the growth of glioblastoma.
Brain Res. 2013 Feb
7;1495:37-51. doi: 10.1016/j.brainres.2012.11.044. Epub 2012 Dec 19.
Abstract
| Related
citations
|
|
|
|
|
|
Clinical
Investigations
|
|
|
|
|
Chinot OL.
Bevacizumab-based
therapy in relapsed glioblastoma: rationale and clinical experience to date.
Expert Rev
Anticancer Ther. 2012 Nov;12(11):1413-27. doi: 10.1586/era.12.128.
Abstract
| Related
citations
|
|
|
De Bonis P, Mangiola A, Pompucci A, Porso
M, Anile C.
High-grade glioma: elderly patients, older treatments.
Expert Rev Neurother. 2012
Nov;12(11):1293-6. doi: 10.1586/ern.12.118.
Abstract |
Full text |
Related citations
|
|
|
Duntze J, Litré CF, Eap C, Théret E, Debreuve A,
Jovenin N, Lechapt-Zalcman E, Metellus P, Colin P, Guillamo JS, Emery E,
Menei P, Rousseaux P, Peruzzi P.
Implanted Carmustine Wafers Followed by Concomitant
Radiochemotherapy to Treat Newly Diagnosed Malignant Gliomas: Prospective,
Observational, Multicenter Study on 92 Cases.
Ann Surg Oncol.
2012 Dec 2. [Epub ahead of print]
Abstract
|
Related citations
|
|
|
Gutenberg A, Bock HC, Reifenberger G, Brück W, Giese A.
Toxicity
and survival in primary glioblastoma patients treated with concomitant plus
adjuvant temozolomide versus adjuvant temozolomide: results of a
single-institution, retrospective, matched-pair analysis.
Acta Neurochir (Wien).
2013 Mar;155(3):429-35. doi: 10.1007/s00701-012-1583-y. Epub 2012 Dec 20.
Abstract
| Related
citations
|
|
|
Hu J, Wen PY, Abrey LE, Fadul CE, Drappatz
J, Salem N, Supko JG, Hochberg F.
A phase II trial of oral gimatecan for recurrent
glioblastoma.
J Neurooncol. 2013
Feb;111(3):347-53. doi: 10.1007/s11060-012-1023-0. Epub 2012 Dec 12.
Abstract
| Full text
|
Related citations
|
|
|
Ko AL, Fink KR, Stelzer KM, Silbergeld DL.
Safety and efficacy of concomitant chemotherapeutic
wafers and iodine-125 seeds for recurrent glioblastoma.
Surg
Neurol Int. 2012;3:137. doi: 10.4103/2152-7806.103644. Epub 2012 Nov
20.
Abstract
| Full text
|
Related citations
|
|
|
Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ,
Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C,
Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I.
Phase II trial of continuous low-dose temozolomide for
patients with recurrent malignant glioma.
Neuro Oncol.
2013 Feb;15(2):242-50. doi: 10.1093/neuonc/nos295. Epub 2012 Dec 14.
Abstract
|
Related citations
|
|
|
Paulsson AK, McMullen KP, Peiffer AM, Hinson WH,
Kearns WT, Johnson AJ, Lesser GJ, Ellis TL, Tatter SB, Debinski W, Shaw EG,
Chan MD.
Limited Margins Using Modern Radiotherapy Techniques
Does Not Increase Marginal Failure Rate of Glioblastoma.
Am J
Clin Oncol. 2012 Dec 1. [Epub ahead of print]
Abstract |
Related citations
|
|
|
Shibui S, Narita Y, Mizusawa J, Beppu T,
Ogasawara K, Sawamura Y, Kobayashi H, Nishikawa R, Mishima K, Muragaki Y,
Maruyama T, Kuratsu J, Nakamura H, Kochi M, Minamida Y, Yamaki T, Kumabe T,
Tominaga T, Kayama T, Sakurada K, Nagane M, Kobayashi K, Nakamura H, Ito T,
Yazaki T, Sasaki H, Tanaka K, Takahashi H, Asai A, Todo T, Wakabayashi T,
Takahashi J, Takano S, Fujimaki T, Sumi M, Miyakita Y, Nakazato Y, Sato A,
Fukuda H, Nomura K.
Randomized trial of chemoradiotherapy and adjuvant
chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for
newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).
Cancer Chemother Pharmacol. 2013 Feb;71(2):511-21. doi:
10.1007/s00280-012-2041-5. Epub 2012 Dec 11.
Abstract
|
Related citations
|
|
|
|
|
|
Brain
Cancer
|
|
|
|
|
|
|
|
Education
|
|
|
|
|
|
down TOP
|
